AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR DAZODALIBEP IN MODERATE-TO-SEVERE SYSTEMIC SJÖGREN'S DISEASE
IMDELLTRA® IN COMBINATION WITH IMFINZI® DEMONSTRATED LANDMARK IMPROVEMENT IN OVERALL SURVIVAL IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER
TEZSPIRE® DEMONSTRATES POSITIVE PHASE 3 RESULTS IN EOSINOPHILIC ESOPHAGITIS ACROSS BOTH CO-PRIMARY AND ALL KEY SECONDARY ENDPOINTS
AMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONS
Precious Metals & Critical Minerals Virtual Investor Conference Presentations Now Available for On-Demand Viewing
CoTec Holdings Corp. Announces Final Closing of Private Placement of Unsecured Convertible Debentures, Total Raise of $20 Million
